M. Wouter Dercksen

Complete responders in patients with HER2-positive metastatic breast cancer: a real-world SONABRE study

Nan Ding, Renee Visserman, Sandra Geurts, Jolien Tol et autres

Background: We aimed to describe real-world complete response (CR) rates, predictors of CR, and survival outcomes in patients treated with first-line pertuzumab, trastuzumab, and chemotherapy for HER2-positive (HER2+) metastatic breast cancer (MBC). Methods: Patients with HER2+ MBC who started first-line pertuzumab, trastuzumab, …

nl (code pays fourni par la source)

Complete responders in patients with HER2-positive metastatic breast cancer: a real-world SONABRE study

Renee Visserman, Sandra M. E. Geurts, Jolien Tol, Birgit E. P. J. Vriens et autres

BACKGROUND: We aimed to describe real-world complete response (CR) rates, predictors of CR, and survival outcomes in patients treated with first-line pertuzumab, trastuzumab, and chemotherapy for HER2-positive (HER2+) metastatic breast cancer (MBC). METHODS: Patients with HER2+ MBC who started first-line pertuzumab, trastuzumab, …

nl (code pays fourni par la source)

543P The association between initial metastatic site and overall survival of patients with single-organ HER2+ metastatic breast cancer (mBC): A real-world SONABRE study

Renee Visserman, Nan Ding, Abenezer Legesse, FW van den Berkmortel et autres

nl, de (code pays fourni par la source)

Receptor Discordance During the Treatment Course of Patients With Metastatic Breast Cancer: Results From the SONABRE Registry

Karlijn Susanna Francisca Maria Hermans, Sandra M. E. Geurts, F. Van den Berkmortel, Jolien Tol et autres

PURPOSE: The aim was to evaluate factors associated with taking 2 biopsies during the disease course of metastatic breast cancer (mBC) and to assess discordance rates for the oestrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). …

nl (code pays fourni par la source)

Shorter post-infusion cooling times at least as effective as longer cooling times — An observational study of taxane- and anthracycline-based chemotherapies in the Dutch Scalp Cooling Registry

Florine F I Breed, W.P.M. Breed, M. Wouter Dercksen, Nicole P. M. Ezendam et autres

nl, de (code pays fourni par la source)

Receptor Discordance During the Treatment Course of Patients with Metastatic Breast Cancer: Results from the Sonabre Registry

Karlijn Susanna Francisca Maria Hermans, Sandra M. E. Geurts, Franchette W.P.J. van den Berkmortel, Jolien Tol et autres

nl (code pays fourni par la source)

395P Receptor status heterogeneity during metastatic breast cancer treatment

Sandra M. E. Geurts, Kirsten Hermans, F. Van den Berkmortel, J. Tol et autres

nl, de (code pays fourni par la source)

LBA20 First-line carboplatin-cyclophosphamide (CC) versus paclitaxel (P) with or without atezolizumab (atezo) for metastatic triple negative breast cancer (mTNBC): Results from a multicenter, randomized phase IIb trial: The Triple-B study (BOOG 2013-01)

Marleen Kok, Rosie Voorthuis, L. De Boo, Annelot G.J. van Rossum et autres

nl, cw (code pays fourni par la source)

Results of the Dutch scalp cooling registry in 7424 patients: analysis of determinants for scalp cooling efficacy

Toni S Brook, Tanja Seetsen, M. Wouter Dercksen, Anne-Marie van Riel et autres

BACKGROUND: Chemotherapy-induced alopecia is a common consequence of cancer treatment with a high psychological impact on patients and can be prevented by scalp cooling (SC). With this multi-center patient series, we examined the results for multiple currently used chemotherapy regimens to offer …

gb, nl, cw, Gabon (code pays fourni par la source)

MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study

Anna van der Voort, Fleur M. Louis, Mette S. van Ramshorst, Rob Kessels et autres

nl (code pays fourni par la source)

Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry

Sandra M. E. Geurts, Khava I. E. Ibragimova, Nan Ding, Marissa Meegdes et autres

PURPOSE: The aim was to determine whether the real-world first-line progression-free survival (PFS) of patients diagnosed with de novo human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer (ABC) has improved since the introduction of pertuzumab in 2013. In addition …

nl, us (code pays fourni par la source)

The HAIR-QoL measure Part 2: Validation of an instrument to measure of the severity and impact of chemotherapy-induced alopecia (CIA)

Julie Winstanley, Laura Libreros‐Peña, Dörthe Schaffrin-Nabe, Azra Arif et autres

Chemotherapy-induced alopecia (CIA) is one of the most common and distressing side effects related to cancer treatment. Few patient-reported outcome measures (PROMs) have been developed specifically to measure the patient-experience of hair loss during chemotherapy treatment. In part I of this research, …

au, co, de, gb, dk, us, nl, jp (code pays fourni par la source)